BroadOak Capital Partners advised Omixon on its sale of the company to Werfen. Omixon, a privately held company based in Budapest, Hungary, develops and commercializes NGS technology for transplant diagnostics. The full press release is below. October 16, 2024 (Barcelona, Spain): Werfen announced today that it has...
BroadOak Capital Partners advised LabConnect on its acquisition of A4P Bio. A4P Bio provides bioanalytical project management solutions and consultancy for clinical trials. The full press release is below. JOHNSON CITY, Tenn., April 22, 2024 /PRNewswire/ -- LabConnect has announced the acquisition of A4P Consulting Ltd (A4P), a scientific...
BroadOak Capital Partners advised ZoBio on the sale of the company to Oncodesign Services. ZoBio is a leading provider of biophysics-based small molecule drug discovery services.The full press release is below.Dijon, France & Leiden, The Netherlands, January 23rd, 2024 – Oncodesign Services (ODS), a leading...
BroadOak Capital Partners advised Bioresource Technology (“BRT”) on the sale of the company to Medix Biochemica. BRT is a leading provider of high-quality base matrices and other critical raw materials for the IVD industry.The full press release is below.Bioresource Technology joins Medix Biochemica GroupMedix Biochemica...
BroadOak Partners advised Aalto Bio Reagents on the sale of the company to Biosynth Carbosynth, a KKR and Ampersand portfolio company. The full press release is below. Addition of Aalto Bio Reagents expands Biosynth Carbosynth’s offer to its clinical diagnostics customers. Staad, 25 May 2022 - Biosynth Carbosynth...
BroadOak’s Q1 Quarterly Review analyzes market trends and M&A transactions across life science tools, diagnostics, and services sectors. Read our full Quarterly Review for more information.Download the full 1Q 2022 BroadOak M&A Newsletter....
BroadOak’s Q4 Quarterly Review analyzes market trends and M&A deals across life sciences tools, diagnostics, and services sectors. Read our full Quarterly Review for more information. Download the full 4Q 2021 BroadOak M&A Newsletter....
Rockland Immunochemicals, Inc. acquired antibodies-online in a transaction financed by BroadOak Capital Partners. Bill Snider, Partner at BroadOak Capital Partners commented: "We are delighted to extend our long-term partnership with Rockland to include financing that supports its acquisition of antibodies-online; a former BroadOak portfolio company. Rockland...
BroadOak Partners advised KCAS, a Vitruvian Partners portfolio company, on the acquisition of FlowMetric, LLC. FlowMetric is a leading provider of flow cytometry and cellular assay R&D services to biotech, pharmaceutical and cell and gene therapy industries. The full press release is below. KCAS Bioanalytical and Biomarker...
BroadOak Partners advises MyChem, LLC on the sale of the company to Maravai LIfeSciences (NASDAQ: MRVI). MyChem is a leading provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics, and research markets. The full press release is below. MyChem’s nucleotide synthesis methods are highly...
Stay connected
Partner with BroadOak